As psychedelics gain more respectability and even go mainstream for possibly treating some mental health disorders, the debate over the safety and effectiveness of these powerful drugs has shifted into high gear. A story in Vice looking at the fallout from one study, which touted psilocybin as a treatment for depression, is emblematic of the surging interest in psychedelics—as well as possible problems with the main players who are promoting its use. Recent landmark studies have suggested that such drugs could be used for treatment-resistant depression, PTSD, smoking, and more, sparking a broad consensus that they are worthy of further research. But as more studies are done, along with what many say is uncritical hype, there are now growing calls to be more circumspect and give these studies more scrutiny. This is also a pivotal moment, the article proposes, to reconsider how psychedelics are talked about and communicated to the public, especially when they are said to “liberate the mind” or “rewire the brain.” This is especially important in the growing for-profit psychedelic market, where results from small studies are routinely used to make advertising claims for psychedelic products and services. As this new ecosystem and interest in psychedelics mature, too much focus on tentative positive findings can obscure safety concerns and negative side effects. Let’s move ahead carefully to study the potential of these drugs, but remain cautious about overstating claims to protect patients.
Street Address
City, State, Zip
Phone Number
Rosenthal Center for AddictIon Studies